These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 28927298

  • 21. Education and imaging: Hepatobiliary and pancreatic: Volume-perfusion CT for monitoring therapy for hepatocellular carcinoma.
    Grözinger G, Plentz R, Horger M.
    J Gastroenterol Hepatol; 2013 Mar; 28(3):588. PubMed ID: 23565554
    [No Abstract] [Full Text] [Related]

  • 22. The Efficacy of Continued Sorafenib Treatment after Radiologic Confirmation of Progressive Disease in Patients with Advanced Hepatocellular Carcinoma.
    Wada Y, Takami Y, Tateishi M, Ryu T, Mikagi K, Saitsu H.
    PLoS One; 2016 Mar; 11(1):e0146456. PubMed ID: 26745625
    [Abstract] [Full Text] [Related]

  • 23. Quantitative therapy response assessment by volumetric iodine-uptake measurement: initial experience in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Dai X, Schlemmer HP, Schmidt B, Höh K, Xu K, Ganten TM, Ganten MK.
    Eur J Radiol; 2013 Feb; 82(2):327-34. PubMed ID: 23246016
    [Abstract] [Full Text] [Related]

  • 24. Early response to anti-tumoral treatment in hepatocellular carcinoma--can quantitative contrast-enhanced ultrasound predict outcome?
    Knieling F, Waldner MJ, Goertz RS, Zopf S, Wildner D, Neurath MF, Bernatik T, Strobel D.
    Ultraschall Med; 2013 Feb; 34(1):38-46. PubMed ID: 23258770
    [Abstract] [Full Text] [Related]

  • 25. Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib.
    Kawaoka T, Aikata H, Murakami E, Nakahara T, Naeshiro N, Tanaka M, Honda Y, Miyaki D, Nagaoki Y, Takaki S, Hiramatsu A, Waki K, Takahashi S, Chayama K.
    Oncology; 2012 Feb; 83(4):192-200. PubMed ID: 22890083
    [Abstract] [Full Text] [Related]

  • 26. Complete and Sustained Off-Therapy Response to Sorafenib in Advanced Hepatocellular Carcinoma.
    Maida M, Macaluso FS, Valenza F, Virdone R.
    J Gastrointestin Liver Dis; 2016 Jun; 25(2):253-5. PubMed ID: 27308660
    [Abstract] [Full Text] [Related]

  • 27. Differences Between CT-Perfusion and Biphasic Contrast-enhanced CT for Detection and Characterization of Hepatocellular Carcinoma: Potential Explanations for Discrepant Cases.
    Perl RM, Portugall J, Hinterleitner C, Hinterleitner M, Kloth C, Walter SS, Bitzer M, Horger MS.
    Anticancer Res; 2021 Mar; 41(3):1451-1458. PubMed ID: 33788737
    [Abstract] [Full Text] [Related]

  • 28. Evaluation of sorafenib for hepatocellular carcinoma by contrast-enhanced ultrasonography: a pilot study.
    Shiozawa K, Watanabe M, Kikuchi Y, Kudo T, Maruyama K, Sumino Y.
    World J Gastroenterol; 2012 Oct 28; 18(40):5753-8. PubMed ID: 23155317
    [Abstract] [Full Text] [Related]

  • 29. [A case of advanced hepatocellular carcinoma successfully treated by liver resection after complete response induced by sorafenib administration].
    Kim Y, Hosoda Y, Kakita N, Yamada Y, Yamasaki M, Nishino M, Okano M, Nagai K, Yasui M, Tsujinaka T.
    Gan To Kagaku Ryoho; 2014 Nov 28; 41(12):2124-6. PubMed ID: 25731444
    [Abstract] [Full Text] [Related]

  • 30. Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma.
    Kuorda H, Abe T, Fujiwara Y, Okamoto T, Yonezawa M, Sato H, Endo K, Oikawa T, Sawara K, Takikawa Y.
    World J Gastroenterol; 2019 May 21; 25(19):2365-2372. PubMed ID: 31148907
    [Abstract] [Full Text] [Related]

  • 31. Advanced Hepatocellular Carcinoma: Pretreatment Contrast-enhanced CT Texture Parameters as Predictive Biomarkers of Survival in Patients Treated with Sorafenib.
    Mulé S, Thiefin G, Costentin C, Durot C, Rahmouni A, Luciani A, Hoeffel C.
    Radiology; 2018 Aug 21; 288(2):445-455. PubMed ID: 29584597
    [Abstract] [Full Text] [Related]

  • 32. Liver computed tomographic perfusion for monitoring the early therapeutic response to sorafenib in advanced hepatocellular carcinoma patients.
    Shen X, Wu D, Tang M, Sun H, Ji Y, Huang C, Zeng M.
    J Cancer Res Ther; 2018 Aug 21; 14(7):1556-1562. PubMed ID: 30589038
    [Abstract] [Full Text] [Related]

  • 33. Hepatocellular carcinoma treated by sorafenib with complete radiological response according to mRECIST criteria: could we stop the treatment? About four cases.
    Poullenot F, Bioulac-Sage P, Laumonier H, Saric J, Carteret T, Blanc JF.
    Acta Oncol; 2014 Mar 21; 53(3):420-3. PubMed ID: 23713857
    [No Abstract] [Full Text] [Related]

  • 34. Early prediction of response of sorafenib on hepatocellular carcinoma by CT perfusion imaging: an animal study.
    Wang Q, Shi G, Wang L, Liu X, Wu R.
    Br J Radiol; 2014 Mar 21; 87(1035):20130695. PubMed ID: 24452058
    [Abstract] [Full Text] [Related]

  • 35. Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Nakazawa T, Hidaka H, Takada J, Okuwaki Y, Tanaka Y, Watanabe M, Shibuya A, Minamino T, Kokubu S, Koizumi W.
    Eur J Gastroenterol Hepatol; 2013 Jun 21; 25(6):683-9. PubMed ID: 23395995
    [Abstract] [Full Text] [Related]

  • 36. Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma.
    Arizumi T, Ueshima K, Takeda H, Osaki Y, Takita M, Inoue T, Kitai S, Yada N, Hagiwara S, Minami Y, Sakurai T, Nishida N, Kudo M.
    J Gastroenterol; 2014 Dec 21; 49(12):1578-87. PubMed ID: 24499826
    [Abstract] [Full Text] [Related]

  • 37. Volume perfusion computed tomography (VPCT)-based evaluation of response to TACE using two different sized drug eluting beads in patients with nonresectable hepatocellular carcinoma: Impact on tumor and liver parenchymal vascularisation.
    Kaufmann S, Horger T, Oelker A, Beck S, Schulze M, Nikolaou K, Ketelsen D, Horger M.
    Eur J Radiol; 2015 Dec 21; 84(12):2548-54. PubMed ID: 26428842
    [Abstract] [Full Text] [Related]

  • 38. Multiparametric imaging for detection and characterization of hepatocellular carcinoma using gadoxetic acid-enhanced MRI and perfusion-CT: which parameters work best?
    Kurucay M, Kloth C, Kaufmann S, Nikolaou K, Bösmüller H, Horger M, Thaiss WM.
    Cancer Imaging; 2017 Jun 28; 17(1):18. PubMed ID: 28659180
    [Abstract] [Full Text] [Related]

  • 39. Clinical features associated with radiological response to sorafenib in unresectable hepatocellular carcinoma: a large multicenter study in Japan.
    Takeda H, Nishikawa H, Osaki Y, Tsuchiya K, Joko K, Ogawa C, Taniguchi H, Orito E, Uchida Y, Izumi N, Japanese Red Cross Liver Study Group.
    Liver Int; 2015 May 28; 35(5):1581-9. PubMed ID: 24836552
    [Abstract] [Full Text] [Related]

  • 40. Pro-angiogenic TIE-2-expressing monocytes/TEMs as a biomarker of the effect of sorafenib in patients with advanced hepatocellular carcinoma.
    Shoji H, Yoshio S, Mano Y, Doi H, Sugiyama M, Osawa Y, Kimura K, Arai T, Itokawa N, Atsukawa M, Aoki Y, Fukai M, Taketomi A, Mizokami M, Kanto T.
    Int J Cancer; 2017 Sep 01; 141(5):1011-1017. PubMed ID: 28555943
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.